Compare ULH & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | MRVI |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.1M | 472.8M |
| IPO Year | 2004 | 2020 |
| Metric | ULH | MRVI |
|---|---|---|
| Price | $14.54 | $3.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $17.00 | $4.57 |
| AVG Volume (30 Days) | 33.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ 39.66 | 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,461,708,000.00 | $185,743,000.00 |
| Revenue This Year | N/A | $11.80 |
| Revenue Next Year | $3.13 | $7.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.78 | $1.67 |
| 52 Week High | $30.76 | $4.11 |
| Indicator | ULH | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 53.21 |
| Support Level | $12.78 | $3.25 |
| Resistance Level | $18.79 | $3.65 |
| Average True Range (ATR) | 1.32 | 0.18 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 5.36 | 56.11 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.